| Company Name: |
Hangzhou Peptidego Biotech Co.,Ltd.
|
| Tel: |
0571-87213919 |
| Email: |
eric@peptidego.com |
| Products Intro: |
Product Name:DA-JC4
CAS:2315504-40-4
Purity:95% or 98% HPLC Package:1mg；5mg；10mg；50mg；100mg,1g or according to customer's detail requirement.
|
| Company Name: |
Hangzhou Sinoda Pharmaceutical Technology Co. LTD
|
| Tel: |
0571-87213919 17306812703 |
| Email: |
3007955328@qq.com |
| Products Intro: |
Product Name:DA-JC4
CAS:2315504-40-4
Purity:95% or 98% HPLC Package:1mg；5mg；10mg；50mg；100mg,1g or according to customer's detail requirement.
|
|
| | DA-JC4 Chemical Properties |
| storage temp. | Store at -20°C, protect from light, stored under nitrogen |
| | DA-JC4 Usage And Synthesis |
| Biological Activity | DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways[1][2][3].
DA-JC4 (1~100 nM; hippocampal cells) inhibits rotenone-induced hippocampal neuron death and significantly suppresses Cyt C, Bax and Caspase activation[3].
DA-JC4 (10 nmol/kg; i.p.; once-daily for 14 days) significantly prevents spatial learning deficits in a Y- maze test and Morris water maze tests, and decreases phosphorylated tau levels in the rat cerebral cortex and hippocampus[1].DA-JC4 (25 nmol/kg; i.p.; 6 days) shows high levels expression of tyrosine Hydroxylase in the s. nigra and increases expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF)[2]. DA-JC4 (50 nmol/kg; i.p.; once-daily for 7 days) improves Parkinson’s disease symptom potentially and enhances neurotransmission[3]. | | References | [1]. Shi L, et al. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behav Brain Res. 2017;327:65-74. [2]. Feng P, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson’s disease. Neuropharmacology. 2018;133:385-394. [3]. Li T, et al. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson’s disease model. Life Sci. 2020;256:117824. |
| | DA-JC4 Preparation Products And Raw materials |
|